

US - OSHA SAFETY DATA SHEET

Issue Date 24-Apr-2015 Revision Date 30-Jul-2019 Version 5

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Product identifier

Product Name Imogam[®] Rabies – HT

Other means of identification

Product Information Vial, 2 mL.

Synonyms Rabies Immune Globulin (Human) USP, Heat Treated

Recommended use of the chemical and restrictions on use

Recommended Use Indicated for individuals suspected of exposure to rabies, particularly severe exposure, with

one exception; persons who have been previously immunized with Rabies Vaccine.

Uses advised against Not available.

Details of the supplier of the safety data sheet

Supplier Address Sanofi Pasteur Discovery Drive Swiftwater, PA 18370

Phone: 1-800-822-2463 (1-800-VACCINE)

Emergency telephone number

24 Hour Emergency Phone 1-703-741-5970 / 1-800-424-9300 CCN # 2118 (CHEMTREC)

2. HAZARDS IDENTIFICATION

Classification

Health Hazards

Not classified.

Physical hazards

Not classified.

OSHA Regulatory Status

This product is a vaccine that is safe for consumers when used according to the label directions. Potential hazards that may occur if product is not used according to the consumer label are as follows throughout the sheet.

Label elements

Emergency Overview

Normal precautions common to safe manufacturing practice should be followed in handling and storage.

Appearance Colorless to light Physical state Liquid Odor Not available.

opalescent.

Hazards not otherwise classified (HNOC)

Not classified as a hazardous substance.

Imogam® Rabies – HT Revision Date 30-Jul-2019

3. COMPOSITION/INFORMATION ON INGREDIENTS

Synonyms

Rabies Immune Globulin (Human) USP, Heat Treated

Chemical Name	CAS No.	Weight-%
Human rabies immunoglobulin 200 to 320 mg of proteins	N/A	10-16
Water	7732-18-5	q.s. to 100

Note: Ingredients below reportable levels are not listed.

4. FIRST AID MEASURES

First aid measures

Eye contact In case of eye contact, immediately flush eyes with fresh water for at least 15 minutes while

holding the eyelids open. Remove contact lenses if worn. Get medical attention if irritation

persists.

Skin Contact In case of contact, remove contaminated clothing. Immediately flush skin with copious

amounts of water for at least 15 minutes. Obtain medical attention if skin reaction occurs.

In case of inhalation, remove to fresh air. If breathing is difficult, administer oxygen. Seek

medical attention immediately.

In case of accidental ingestion, wash out mouth with copious amounts of water. Seek medical

attention if needed. Do not induce vomiting unless directed by medical personnel. Never give

anything by mouth to an unconscious person.

Self-protection of the first aiderDo not use mouth-to-mouth method if victim ingested or inhaled the substance; give artificial

respiration with the aid of a pocket mask equipped with a one-way valve or other proper

respiratory medical device.

Most important symptoms and effects, both acute and delayed

Symptoms Common effects of the vaccine include the following: tenderness, pain, erythema, induration,

pruritus, and regional adenopathy of the injection site; headache; malaise.

Indication of any immediate medical attention and special treatment needed

Note to physicians Treat symptomatically.

5. FIRE-FIGHTING MEASURES

Suitable extinguishing media

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media None known.

Specific hazards arising from the chemical

Not available.

Hazardous combustion products Not available.

Explosion data

Sensitivity to Mechanical Impact Not available. Sensitivity to Static Discharge None known.

Protective equipment and precautions for firefighters

As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective

Imogam® Rabies - HT

Revision Date 30-Jul-2019

gear.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

Personal precautions Wear appropriate personal protective equipment (see Section 8).

Environmental precautions

Environmental precautions See Section 12 for additional ecological information.

Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Wipe up with absorbent material (e.g. cloth) for disposal. Area where spill occurred can be

cleaned with the regular cleaning materials designated for the area.

7. HANDLING AND STORAGE

Precautions for safe handling

Advice on safe handling Handle in accordance with good industrial hygiene and safety practice.

Conditions for safe storage, including any incompatibilities

Storage Conditions Store at 2° to 8°C (35° to 46°F). Do not freeze.

Incompatible materials Not available.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Control parameters

Exposure Guidelines This product, as supplied, does not contain any hazardous materials with Occupational

Exposure Limits (OEL) established by the region specific regulatory bodies.

Appropriate engineering controls

Engineering Controls Used as supplied, no special engineering controls are needed when administering the

vaccine.

Individual protection measures, such as personal protective equipment

Eye/face protection In laboratory or industrial settings, gloves and lab coats are recommended.

Skin and body protection In laboratory or industrial settings, gloves and lab coats are recommended.

Respiratory protection Used as supplied, general room ventilation is acceptable and no special respiratory

protection is needed when administering the vaccine.

General Hygiene Considerations Always observe good personal hygiene measures, such as washing after handling the

material and before eating, drinking, and/or smoking. Routinely wash work clothing and

protective equipment.

9. PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Physical state Liquid **Appearance** Opalescent Odor Not available. Not available. Color Colorless **Odor threshold**

Values Remarks • Method **Property**

Not available. Melting point/freezing point Not available. Boiling point / boiling range Not available.

Imogam® Rabies - HT

Revision Date 30-Jul-2019

Flash point Not available. **Evaporation rate** Not available. Flammability (solid, gas) Not available.

Flammability Limit in Air

Upper flammability limit: Not available. Lower flammability limit: Not available. Vapor pressure Not available. Vapor density Not available. **Specific Gravity** Not available. Water solubility Not available. Solubility in other solvents Not available. **Partition coefficient** Not available. **Autoignition temperature** Not available. **Decomposition temperature** Not available. Kinematic viscosity Not available. Dynamic viscosity Not available. **Explosive properties** Not available. Oxidizing properties Not available.

Other Information

Softening point Not available. Molecular weight Not available. **VOC Content (%)** Not available. Not available. Density **Bulk density** Not available.

10. STABILITY AND REACTIVITY

Reactivity

Not reactive under normal conditions.

Chemical stability

Stable under normal conditions.

Possibility of Hazardous Reactions

None under normal handling.

Hazardous polymerization Hazardous polymerization does not occur.

Conditions to avoid

Not available.

Incompatible materials

Not available.

Hazardous Decomposition Products

None under normal use conditions.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Product Information No data available.

Inhalation No impact known or expected under normal use.

Eve contact No impact known or expected under normal use.

Skin Contact No impact known or expected under normal use.

Ingestion No impact known or expected under normal use.

Imogam® Rabies - HT

Revision Date 30-Jul-2019

Information on toxicological effects

Symptoms Common effects of the vaccine include the following: tenderness, pain, erythema, induration,

pruritus, and regional adenopathy of the injection site; headache; malaise.

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Skin corrosion/irritation Not available. Serious eye damage/eye irritation Not available. Irritation Not available. Corrosivity Not available. Sensitization Not available. Germ cell mutagenicity Not available. Carcinogenicity Not available.

Reproductive toxicity Animal reproduction studies have not been conducted with Imogam® Rabies – HT. It is also

> not known whether Imogam® Rabies - HT can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Immunoglobulins are excreted in

maternal milk.

Developmental Toxicity Not available. **Teratogenicity** Not available. STOT - single exposure Not classified. STOT - repeated exposure Not classified. Chronic toxicity Not available. **Subchronic toxicity** Not available. **Target Organ Effects** Not available. **Neurological effects** Not available. Other adverse effects Not available. **Aspiration hazard** Not available.

Numerical measures of toxicity - Product Information

12. ECOLOGICAL INFORMATION

Ecotoxicity

Not available.

Persistence and degradability

Not available.

Bioaccumulation

Not available.

Mobility

Not available.

Other adverse effects Not available.

13. DISPOSAL CONSIDERATIONS

Waste treatment methods

Disposal of wastes Disposal should be in accordance with applicable regional, national and local laws and

regulations.

Contaminated packaging Disposal should be in accordance with applicable regional, national and local laws and

regulations.

US EPA Waste Number Not applicable.

California Hazardous Waste Codes Not applicable.

14. TRANSPORT INFORMATION

Imogam[®] Rabies – HT

Revision Date 30-Jul-2019

DOT Not regulated.

TDG Not regulated.

MEX Not regulated.

ICAO (air) Not regulated.

IATA Not regulated.

IMDG Not regulated.

RID Not regulated.

ADR Not regulated.

ADN Not regulated.

15. REGULATORY INFORMATION

US Federal Regulations

SARA 313

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.

SARA 311/312 Hazard Categories

Acute health hazardNoChronic Health HazardNoFire hazardNoSudden release of pressure hazardNoReactive HazardNo

CWA (Clean Water Act)

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42).

CERCLA

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355).

US State Regulations

California Proposition 65

No component is on the Proposition 65 list.

U.S. State Right-to-Know Regulations

This drug is regulated by the Food and Drug Administration and is therefore exempt from State Right-to-Know Regulations.

16. OTHER INFORMATION

Prepared By IES Engineers Issue Date 24-Apr-2015 Revision Date 30-Jul-2019

Revision Note Updated Section 11: Reproductive Toxicity. Revised by Sanofi Pasteur.

Disclaimer

Sanofi Pasteur considers that the information contained in this Safety Data Sheet is accurate, and while it is provided in

good faith, it is without warranty of any kind, expressed or implied. The information contained herein is designated only as guidance for safe handling, storage and use of the substance and is not a specification nor does it guarantee any specific properties. Only competent personnel, within a controlled environment should handle all chemicals. Sanofi Pasteur cannot be held liable for any loss, injury or damage from contact with the product.

End of Safety Data Sheet